INCYTE Corporation (INCY)

HEALTH CARE: PHARMACEUTICALS
SIC: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH

1801 AUGUSTINE CUT-OFF WILMINGTON, DE 19803

Incyte is a biopharmaceutical company focused on developing and commercializing proprietary small molecule drugs for oncology and inflammation. Co.'s pipeline includes compounds in several stages, ranging from preclinical to commercialized product. Co.'s compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used as a treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. Co. has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company.

Data based on most recent fiscal year report
Market Cap17.282 Billion Shares Outstanding211.04 Million Avg Volume2.903 Million
1-Yr BETA vs S&P TR Current Ratio4.01 Quick Ratio3.99
View SEC Filings from INCY instead.
Q2 2019 All Institutions Hedge Funds 1
To trade INCY now:
Filers who had this stock in their top 10: 5 2 (0.21%)
13F Filers holding this stock: 491 59 (6.1%)
Aggregate 13F shares on 06/30/2019: 197.536 Million 47.174 Million
Aggregate 13F shares on 03/31/2019: 194.414 Million 48.346 Million
Percent change: 1.61% -2.42%
Funds creating new positions: 62 14
Funds Adding to an existing position: 177 16
Funds closing out their position: 65 20
Funds reducing their position: 176 19
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding INCY (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

5 Thousand total shares from 2 transactions

Exercise Derivative Conversion (M)

2.7 Thousand total shares from 3 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

PASQUALE MARIA E EVP & GENERAL COUNSEL

  • Officer
18,680 2019-10-10 7

BAKER BROS. ADVISORS LP

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

  • Director
  • 10% Owner
0 2019-10-10 7

FLANNELLY BARRY P

  • Director
397 2019-10-01 9

GRYSKA DAVID W

  • Director
48,013 2019-10-01 0

DE SCHUTTER RICHARD U

  • Director
283,206 2019-09-30 0

DIXON WENDY L

  • Director
12,340 2019-09-30 5

BROOKE PAUL A

  • Director
241,320 2019-09-30 5

CLANCY PAUL J

  • Director
2,226 2019-09-30 4

BIENAIME JEAN JACQUES

  • Director
7,274 2019-09-30 7

FOUSE JACQUALYN A

  • Director
2,831 2019-09-30 5

EMMENS MATTHEW

  • Director
0 2019-09-30 0

WHITFIELD ROY A

  • Director
208,250 2019-09-25 0

SWAIN PAULA J EVP, HUMAN RESOURCES

  • Officer
41,612 2019-09-18 11

DALY JAMES M

  • Director
0 2019-09-09 0

FRIEDMAN PAUL A

  • Director
315,531 2019-08-02 2

HOPPENOT HERVE CHAIRMAN / CEO

  • Officer
  • Director
  • PRESIDENT
294,822 2019-07-15 6

WENQING YAO EVP, HEAD OF DISCOVERY CHEM

  • Officer
45,308 2019-07-15 6

TROWER PAUL PRINCIPAL ACCOUNTING OFFICER

  • Officer
17,306 2019-07-15 5

STEIN STEVEN H EVP & CHIEF MEDICAL OFFICER

  • Officer
16,473 2019-07-15 6

IYENGAR VIJAY K EVP GPS, BD, & LICENSING

  • Officer
18,539 2019-07-05 5

DHANAK DASHYANT EVP & CHIEF SCIENTIFIC OFFICER

  • Officer
13,639 2019-07-02 3

LEVY RICHARD S

  • Director
0 2019-06-27 0

HASTINGS DAVID C

  • Director
0 2019-06-19 0

MORRISSEY MICHAEL JAMES EVP, HEAD OF TECH. OPERATIONS

  • Officer
43,050 2019-06-19 1

DICKINSON JONATHAN ELLIOTT EVP, GENERAL MANAGER, EUROPE

  • Officer
24,844 2019-06-19 1

HUBER REID M

  • Director
0 2019-06-13 0

BAKER BROS. ADVISORS LP

14159, L.P.

667, L.P.

BAKER BROS. ADVISORS (GP) LLC

BAKER BROTHERS LIFE SCIENCES LP

BAKER FELIX

BAKER JULIAN

  • Director
  • 10% Owner
32,431,899 2019-06-06 7

ANDREWS PATRICIA S

  • Director
0 2019-05-17 0

STAMOULIS CHRISTIANA

  • Director
37,175 2019-03-07 2

SIEGEL ERIC H. EVP, GENERAL COUNSEL

  • Officer
21,053 2017-09-13 0

CHARDONNET LAURENT

  • VICE PRESIDENT AND TREASURER
2,905 2015-03-30 0

ARIKO BARRY A

  • Director
45,834 2015-03-12 0

BAKER BROS. ADVISORS (GP) LLC

  • Director
  • 10% Owner
0 2013-07-01 0

BAKER BROTHERS LIFE SCIENCES LP

  • Director
12,445,783 2013-06-11 0

14159, L.P.

  • Director
370,839 2013-06-11 0

667, L.P.

  • Director
2,038,937 2013-06-11 0

BAKER JULIAN

BAKER FELIX

BAKER BROS ADVISORS LLC

667, L.P.

BAKER BROTHERS LIFE SCIENCES LP

14159, L.P.

  • Director
  • 10% Owner
15,023,952 2013-06-11 0

BAKER JULIAN

  • Director
  • 10% Owner
0 2013-05-30 0

FBB ASSOCIATES

  • Director
173,897 2012-07-26 0

FBB2 LLC

  • Director
  • 10% Owner
15,110 2012-06-15 0

BAKER BROS ADVISORS LLC

  • 10% Owner
0 2012-04-12 0

BAKER BROTHERS LIFE SCIENCES CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
2,328,863 2012-03-12 0

14159 CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
57,704 2012-03-12 0

BAKER BIOTECH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • 10% Owner
232,011 2012-03-12 0

BAKER BROS. CAPITAL (GP), LLC

BAKER FELIX

BAKER JULIAN

  • 10% Owner
0 2012-01-27 0

BAKER / TISCH CAPITAL (GP), LLC

BAKER JULIAN

BAKER FELIX

  • Director
  • 10% Owner
450,461 2011-12-30 0

NIBLACK JOHN F

  • Director
0 2011-05-20 0

SCHRECK PATRICIA A EVP, GENERAL COUNSEL

  • Officer
4,500 2011-05-09 0

METCALF BRIAN W CHIEF DRUG DISCOVERY SCIENTIST

  • Officer
66,504 2011-04-11 0

FRIEDMAN STEVEN M. EVP, BIOLOGY & PRECLINICAL DEV

  • Officer
0 2010-05-18 0

KELLER JOHN A CHIEF BUSINESS OFFICER

  • Officer
0 2008-02-08 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

PASQUALE MARIA E - Officer EVP & GENERAL COUNSEL

2019-10-10 M 77 d 4,740 18,680.00 direct

PASQUALE MARIA E - Officer EVP & GENERAL COUNSEL

2019-10-10 M 77 $65.36 a 18,680 18,680.00 direct

FOUSE JACQUALYN A - Director

2019-09-30 A 251 $74.23 a 2,831 2,831.00 direct

BAKER BROS. ADVISORS LP - Director - > 10% Owner see footnotes

667, L.P. - Director - > 10% Owner see footnotes

BAKER BROS. ADVISORS (GP) LLC - Director - > 10% Owner see footnotes

BAKER BROTHERS LIFE SCIENCES LP - Director - > 10% Owner see footnotes

BAKER FELIX - Director - > 10% Owner see footnotes

BAKER JULIAN - Director - > 10% Owner see footnotes

2019-09-30 A 364 $74.23 a 29,291,207 32,712,020.00 indirect

BIENAIME JEAN JACQUES - Director

2019-09-30 A 219 $74.23 a 7,274 7,274.00 direct

BAKER BROS. ADVISORS LP - Director - > 10% Owner see footnotes

667, L.P. - Director - > 10% Owner see footnotes

BAKER BROS. ADVISORS (GP) LLC - Director - > 10% Owner see footnotes

BAKER BROTHERS LIFE SCIENCES LP - Director - > 10% Owner see footnotes

BAKER FELIX - Director - > 10% Owner see footnotes

BAKER JULIAN - Director - > 10% Owner see footnotes

2019-09-30 A 364 $74.23 a 2,827,440 32,712,020.00 indirect

CLANCY PAUL J - Director

2019-09-30 A 266 $74.23 a 2,226 2,226.00 direct

DIXON WENDY L - Director

2019-09-30 A 225 $74.23 a 12,340 12,340.00 direct

BROOKE PAUL A - Director

2019-09-30 A 304 $74.23 a 201,320 241,320.00 direct

SWAIN PAULA J - Officer EVP, HUMAN RESOURCES

2019-09-18 M 2,500 d 14,139 41,612.00 direct

SWAIN PAULA J - Officer EVP, HUMAN RESOURCES

2019-09-18 S 2,500 $80.00 d 41,612 41,612.00 direct

SWAIN PAULA J - Officer EVP, HUMAN RESOURCES

2019-09-18 M 2,500 $64.55 a 44,112 41,612.00 direct

FLANNELLY BARRY P - Officer EVP & GENERAL MANAGER US

2019-09-17 S 2,491 $77.71 d 16,757 16,757.00 direct

PASQUALE MARIA E - Officer EVP & GENERAL COUNSEL

2019-09-09 M 76 $65.36 a 18,603 18,603.00 direct

PASQUALE MARIA E - Officer EVP & GENERAL COUNSEL

2019-09-09 M 76 d 4,817 18,603.00 direct
Click here to report any possible errors with this stock listing.

Elevate your investments